Criteria for the appropriate drug utilisation of immunoglobulin

PharmacoEconomics

Volumn 9, Issue 5, 1996, Pages 417-429

  Thürmann, Petra ^a   Harder, Sebastian ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGAMMAGLOBULINEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOIMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTAMINATION; DRUG INDICATION; DRUG USE; GUILLAIN BARRE SYNDROME; HEPATITIS C VIRUS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE MYELOMA; NEWBORN; PHARMACOECONOMICS; PRIORITY JOURNAL; REVIEW; SEPTICEMIA;

EID: 0029947345     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199609050-00005     Document Type: Review

References (86)

1. Harder S, Böger R, Bode-Böger S, et al. Drug utilisation review in German hospitals [abstract]. Eur J Clin Pharmacol 1994; 47: 102
2. Thürmann P, Harder S. Determinants of hospital drug expenditures in Western Europe. PharmacoEconomics 1993; 4 (3): 157-61
3. Chapel HM, for the Consensus Panel for the Diagnosis and Management of Primary Antibody Deficiencies. Consensus on diagnosis and management of primary antibody deficiencies. BMJ 1994; 308: 581-5
4. National Institutes of Health Consensus Conference. Intravenous immunoglobulin: prevention and treatment of disease. JAMA 1990; 264: 3189-93
5. Keller T, McGrath K, Newland A, et al., for the Australasian Society of Blood Transfusion. Indications for use of intravenous immunoglobulin. Med J Aust 1993; 159: 204-6
6. Stiehm ER, Ashida E, Kim S, et al. Intravenous immunoglobulins as therapeutic agents (UCLA Conference). Ann Intern Med 1987; 107: 367-82
7. Cohn EJ, Gurd FRN, Suigenor DM, et al. A system for the separation of the components of human blood: quantitative procedure for the separation of the protein components of human plasma. J Am Chem Soc 1950; 72: 465-70
8. Jungi TW, Santer M, Lerch PG, et al. Effect of various treatments of gamma-globulin (IgG) for achieving intravenous tolerance on the capacity to interact with human monocyte Fc receptors: a comparative study. Vox Sang 1986; 51: 18-26
9. Morell A, Skavril F. Struktur und biologische Eigenschaften von Immunglobulinen: II. Eigenschaften von γ-Globulin-Präparaten. Schweiz Med Wochenschr 1980; 110: 80-5
10. Weisman LE. Advances in the treatment of neonatal sepsis and meningitis. Isr J Med Sci 1994; 30: 455-8
11. Janeway CA, Merler E, Rosen FS, et al. Intravenous gamma globulin: metabolism of gamma globulin fragments in normal and agammaglobulinemic persons. N Engl J Med 1968; 278: 919-23
12. González M, Murature DA, Fidelio GD. Thermal stability of human immunoglobulins with sorbitol. Vox Sang 1995; 68: 1-4
13. Yang YH, Ngo C, Yeh IN, et al. Antibody Fc functional activity of intravenous immunoglobulin preparations treated with solvent-detergent for virus inactivation. Vox Sang 1994; 67: 337-44
14. Nydegger U. Alte und neue Aspekte der intravenösen Immunglobulintherapie. Schweiz Med Wochenschr 1994; 124: 5-25
15. Nowak T, Gregersen J-P, Klockmann U, et al. Virus safety of human immunoglobulins: efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure. J Med Virol 1992; 36: 209-16
16. Commission of the European Community. Validation of virus removal and inactivation procedures. 1991. 111/8115/89-EN-Final 1991. In: Feiden K, editor. Arzneimittelprüf richtlinien. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1995
17. Imbach P, Perret BA, Babington R, et al. Safety of intravenous immunoglobulin preparations: a prospective multicenter study to exclude the risk of non-A, non-B hepatitis. Vox Sang 1991; 61: 1-4
18. Louie RE, Galloway CJ, Dumas ML, et al. Inactivation of hepatitis C virus in low pH intravenous immunoglobulin. Biologicals 1994; 22: 13-9
19. Suomela H. Viral inactivation of blood and blood products. WHO LBS 1992; 92-5
20. Uemura Y, Yang YH, Heldebrant CM, et al. Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin. Vox Sang 1994; 67: 1-9
21. Kempf C, Jentsch P, Poirier B, et al. Virus inactivation during production of intravenous immunoglobulin. Transfusion 1991; 31: 423-7
22. Bjøro K, Frøland SS, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immunoglobulin. N Engl J Med 1994; 331: 1607-11
23. Lane RS. Non-A, non-B hepatitis from intravenous immunoglobulin. Lancet 1983; 2: 974-5
24. Weisman LE. The safety of intravenous immunuglobulin preparations. Isr J Med Sci 1994; 30: 459-63
25. Morell A, Skavril F, Barandun S. IgG-Subklassen der menschlichen Immunglobuline. Basel: S. Karger, 1975
26. Hammarström L, Gardulf A, Hammarström V, et al. Systemic and topical immunoglobulin treatment in immunocompromised patients. Immunol Rev 1994; 139: 43-70
27. Imbach P, Barundun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura. Lancet 1981; 1: 1228-31
28. Andersson UG, Björk L, Skansén-Saphir U, et al. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 1993; 79: 211-5
29. Glöckner WM. Kinetik von Immunoglobulin G nach intravenöser und intramuskulärer Applikation. In: Kornhuber B, editor. Patient - Infektion - Immunoglobulin. Berlin: Springer Verlag, 1984: 33-8
30. Thürmann PA, Sonnenburg-Chatzopoulos C, Lissner R. Pharmacokinetic characteristics and tolerability of a novel intravenous immunoglobulin preparation. Eur J Clin Pharmacol 1995; 49: 237-42
31. Hagenbeek A, Brummelhuis HGJ, Donkers A, et al. Rapid clearance of cytomegalovirus-specific IgG after repeated intravenous infusions of human immunoglobulin into allogeneic bone marrow transplant recipients. J Infect Dis 1987; 155: 897-902
32. Mankarious S, Lee M, Fischer S, et al. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med 1988; 112: 634-40
33. Fahey JF, Robinson AG. Factors controlling serum γ-globulin concentration. J Exp Med 1963; 118: 845-68
34. Theobald K, Högy B. Pharmacokinetics of single and multiple infusions of 5S intravenous immunoglobulin. Vox Sang 1995; 68: 5-8
35. Dwyer J. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326: 107-16
36. Stiehm ER. New uses for intravenous immune globulin. N Engl J Med 1991; 325: 123-5
37. Schaad UB, Gianella-Borradori A, Perret B, et al. Intravenous immunoglobulin in symptomatic paediatric human immunodeficiency virus infection. Eur J Pediatr 1988; 147: 300-3
38. Hague RA, Yap PL, Mok JYQ, et al. Intravenous immunoglobulin in HIV infection: evidence for the efficacy of treatment. Arch Dis Child 1989; 64: 1146-50
39. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group. Intravenous immunoglobulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991; 325: 73-80
40. Foon KA, Rai KR, Gale RP. Chronic lymphocytic leukemia: new insights into biology and therapy. Ann Intern Med 1990; 113: 525-39
41. Griffiths H, Brennan V, Lea J, et al. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood 1989; 73: 366-8
42. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia: a randomized, controlled clinical trial. N Engl J Med 1988; 319: 902-7
43. Schedel I. Application of immunoglobulin preparations in multiple myeloma. In: Morell A, Nydegger UE, editors. Clinical use of intravenous immunoglobulins. London: Academic Press, 1986: 123-32
44. Chapel HM, Lee M, Hargreaves R, et al., for the UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. Lancet 1994; 343: 1059-63
45. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991; 325: 81-6
46. Pirofsky B, Kinzey DM. Intravenous immunoglobulins: a review of their uses in selected immunodeficiency and autoimmune diseases. Drugs 1992; 43: 6-14
47. Wordell CJ, Stubits EA, Tietze KJ, et al. Immune globulin in the treatment of autoimmune thrombocytopenic purpura. Clin Pharm 1985; 4: 206-13
48. ASHP therapeutic guidelines for intravenous immunoglobulin. Clin Pharm 1992; 11: 117-36
49. Kurlander R, Coleman RE, Moore J, et al. Comparison of the efficacy of a two-day and a five-day schedule for infusing intravenous gamma globulin in the treatment of immune thrombocytopenic purpura in adults. Am J Med 1987; 83 (4A): 17-24
50. Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984; 2: 1055-8
51. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315: 341-7
52. Guglielmo BJ, Wong-Beringer A, Linker CA. Immune globulin therapy in allogeneic bone marrow transplant: a critical review. Bone Marrow Transplant 1994; 13: 499-510
53. Winston DJ, Ho WG, Lin CH, et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 1987; 106: 12-8
54. Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323: 705-12
55. Emanuel D, Taylor J, Brochstein J, et al. The use of intravenous immune globulin as prophylaxis for the infectious complications of allogeneic marrow transplantation [abstract no. 1075]. Blood 1992; 80 Suppl. 1: 271A
56. Condie RM, O'Reilly RJ. Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune native, unmodified cytomegalovirus globulin: randomized trial in bone marrow transplant recipients. Am J Med 1984; 76 Suppl. 3A: 141
57. Kubanek B, Ernst P, Ostendorf P, et al. Preliminary data of a controlled trial of intravenous hyperimmune globulin in the prevention of cytomegalovirus infection in bone marrow transplant recipients. Transplant Proc 1985; 17: 468-9
58. Snydman DR, Werner BG, Tilney NL, et al. Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: comparison of the randomized and open-label trials. Transplant Proc 1991; 23 (1): 1357-60
59. Zbrozek AS. The cost of cytomegalovirus disease in renal transplantation [letter]. Transplantation 1994; 57 (1): 165
60. Conti DJ, Freed BM, Lempert N. Prophylactic immunoglobulin therapy improves the outcome of renal transplantation in recipients at risk for primary cytomegalovirus disease. Transplant Proc 1993; 25: 1421-2
61. Conti DJ, Freed BM, Gruber SA, et al. Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. Arch Surg 1994; 129: 443-7
62. Nicol DL, MacDonald AS, Belitsky P, et al. Reduction by combination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary CMV disease in renal transplant recipients. Transplantation 1993; 55 (4): 841-6
63. Stratta RJ, Taylor RJ, Bynon JS, et al. Viral prophylaxis in combined pancreas-kidney transplant recipients. Transplantation 1994; 57 (4): 506-12
64. The Intravenous Immunoglobulin Collaborative Study Group. Prophylactic intravenous administration of standard immunoglobulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 1992; 327: 234-40
65. Glinz W, Grob PJ, Nydegger UE, et al. Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma. Intensive Care Med 1985; 11: 288-94
66. Just H-M, Metzger M, Vogel W, et al. Einfluß einer adjuvanten Immunglobulintherapie auf Infektionen bei Patienten einer operativen Intensiv-Therapie-Station. Klin Wochenschr 1986; 64: 245-56
67. Dominioni L, Dionigi R, Zanello M, et al. Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Arch Surg 1991; 126: 236-40
68. Schedel I, Dreikhausen U, Nentwig B, et al. Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med 1991; 19: 1104-13
69. Nazzari C, Gaeta A, Lun MT, et al. Effect of intravenous immunoglobulin on opsonic activity and TNF production in patients at high risk for sepsis syndrome. Microbiologica 1993; 16: 251-8
70. Jesdinsky HJ, Tempel G, Castrup HJ, et al. Cooperative group of additional immunoglobulin therapy in severe bacterial infections: results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitis. Klin Wochenschr 1987; 65: 1132-8
71. Siber GR. Immunoglobulin to prevent nosocomial infections. N Engl J Med 1992; 327: 269-71
72. Pilz P, Fateh-Moghadam S, Viell B, et al. Supplemental immunoglobulin therapy in sepsis and septic shock - comparison of mortality under treatment with polyvalent i.v. immunoglobulin versus placebo. Theor Surg 1993; 8: 61-83
73. Chirico G, Rondini G, Plebani A, et al. Intravenous gamma-globulin therapy for prophylaxis of infection in high-risk neonates. J Pediatr 1987; 110: 437-42
74. Baker CJ, Melish ME, Hall RT, et al. Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. N Engl J Med 1992; 327: 213-9
75. Weisman LE, Stoll BJ, Kueser T, et al. Intravenous immunoglobulin therapy of neonatal sepsis. J Pediatr 1992; 121: 434-43
76. Magny J-F, Bremard-Oury C, Brault D, et al. Intravenous immunoglobulin therapy for prevention of infection in high risk premature infants: report of a multicenter, double-blind study. Pediatrics 1991; 88: 437-43
77. Fanaroff AA, Korones SB, Wright LL, et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. N Engl J Med 1994; 330: 1107-13
78. Kickler T, Braine HG, Pinatadosi S, et al. A randomized placebo controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. Blood 1990; 75: 313-6
79. Schuchardt V. Behandlung neuromuskulärer Erkrankungen mit 7S-Ig. In: Zierz S, Langner G, Naß WP, editors. Immunmodulatorische Therapie mit Immunglobulinen bei Infektionen und Autoimmunerkrankungen. Jena: Universitätsverlag Jena, 1995
80. Achiron A, Pras E, Gilad R, et al. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol 1992; 49: 1233-6
81. Coulam CB. Alternative treatment to lymphocyte immunization for treatment of recurrent spontaneous abortion. Am J Reprod Immunol 1994; 32: 286-9
82. Mazer BD, Gelfand EW. An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma. J Allergy Clin Immunol 1991; 87; 976-83
83. Van der Méche FGA, Schmitz PIM. The Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré Syndrome. N Engl J Med 1992; 326: 1123-9
84. Vermeulen M, van Doorn PA, Brand A, et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993; 56 (1): 36-9
85. Ratko TA, Burnett DA, Foulke GE, et al. Recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA 1995; 273: 1865-70
86. Consensus on IVIG [editorial]. Lancet 1990; 336: 470-2